Objective To investigate the association of serum amyloid A (SAA) level with myocardial ischemia severity, cardiac function, and medium-term prognosis in patients with acute myocardial infarction (AMI). Methods This prospective cohort study enrolled 102 patients diagnosed with AMI at Henan Provincial Staff Hospital between January 2021 and May 2024. Patients were stratified by SAA level within 24 hours of admission using a cutoff of 100 mg/L, yielding a high-SAA group (n=34) and a low-SAA group (n=68). Baseline clinical characteristics; indices of myocardial ischemic severity, including ST-segment elevation amplitude and Thrombolysis in Myocardial Infarction (TIMI) flow grade; cardiac function parameters, including left ventricular ejection fraction (LVEF) and N-terminal pro-B-type natriuretic peptide (NT-proBNP); and SAA levels were collected. Patients were followed from admission, with a mean follow-up of 14.75±2.60 months. The primary endpoint was major adverse cardiovascular events (MACE). Spearman rank correlation was used to assess correlations between SAA and each index. Multivariable regression models were constructed with myocardial ischemic severity and cardiac function parameters as dependent variables, respectively. Cox proportional hazards models were used to evaluate the predictive value of SAA for MACE, and subgroup analyses with interaction tests were performed. Results (1) No significant between-group differences were observed in demographic characteristics, cardiovascular risk factors, or MI type (all P>0.05), indicating comparable baseline characteristics. The high-SAA group had higher levels of cardiac troponin I (cTnI), creatine kinase-MB isoenzyme, C-reactive protein (CRP), and global registry of acute coronary events (GRACE) scores than the low-SAA group (all P<0.05). (2) The high-SAA group showed greater ST-segment elevation amplitude, a lower proportion of TIMI flow grade 2-3, lower LVEF, and higher NT-proBNP levels (all P<0.05). (3) Spearman correlation analysis revealed that SAA level was positively correlated with ST-segment elevation amplitude (rₛ=0.328, P<0.001) and NT-proBNP (rs=0.412, P<0.001), and negatively correlated with TIMI flow grade (rₛ=−0.256, P=0.001) and LVEF (rₛ=−0.287, P=0.003). (4) Multivariable regression analysis showed that after uniform adjustment for sex, age, body mass index (BMI), hypertension, diabetes, cTnI, and CRP, high SAA level was an independent factor for impaired TIMI flow (OR=0.862, 95%CI: 0.759-0.979, P=0.022), and was independently positively associated with ST-segment elevation amplitude and NT-proBNP, and independently negatively associated with LVEF (all P<0.05). (5) During follow-up, MACE occurred in 25 patients (24.51%). After additional adjustment for GRACE score, lnNT-proBNP, and TIMI flow grade on the basis of core confounders, multivariable Cox regression analysis demonstrated that high SAA level was an independent predictor of MACE (HR=1.820, 95%CI: 1.210-2.740, P=0.004). Subgroup analysis revealed a significant interaction between MI type (STEMI vs. NSTEMI) and SAA (P=0.045), whereas no significant interaction was observed for age (P=0.123). Conclusion Elevated SAA level is independently associated with more severe myocardial ischemia, worse cardiac function, and higher medium-term MACE risk in patients with AMI, suggesting its potential clinical value in disease severity assessment and prognostic prediction.